Vanda Pharmaceuticals Inc.
Hedge Funds Holdings
Last updated:
Vanda Pharmaceuticals Inc.‘s stocks are currently a part of 157 hedge funds’ portfolios, which represents 84.61% of the total amount of its stocks outstanding. This makes up a total of 48.07M shares of Vanda Pharmaceuticals Inc.. Compared to the previous quarter, the number fell by -14.16% or -7.92M shares fewer. As for the holding position changes, 39.49% (62) of current hedge fund investors increased the number of shares held, 29.94% (47) of current holders sold a part of the shares held, and 12.74% (20) closed the holdings completely. 23 hedge funds are new holders of Vanda Pharmaceuticals Inc. stock in Q3 2022, it is 14.65% of total holders.
Hedge funds holding Vanda Pharmaceuticals (Q4 2017 – Q3 2022)
| Q4 2017 | 125 |
|---|---|
| Q1 2018 | 131 |
| Q2 2018 | 135 |
| Q3 2018 | 158 |
| Q4 2018 | 182 |
| Q1 2019 | 176 |
| Q2 2019 | 161 |
| Q3 2019 | 164 |
| Q4 2019 | 175 |
| Q1 2020 | 156 |
| Q2 2020 | 160 |
| Q3 2020 | 160 |
| Q4 2020 | 174 |
| Q1 2021 | 186 |
| Q2 2021 | 178 |
| Q3 2021 | 176 |
| Q4 2021 | 194 |
| Q1 2022 | 181 |
| Q2 2022 | 165 |
| Q3 2022 | 157 |
Hedge funds changes in Vanda Pharmaceuticals positions (Q4 2017 – Q3 2022)
| Q4 2017 | 13 | 49 | 42 | 25 | -4 |
|---|---|---|---|---|---|
| Q1 2018 | 25 | 40 | 44 | 16 | 6 |
| Q2 2018 | 16 | 54 | 43 | 12 | 10 |
| Q3 2018 | 37 | 58 | 41 | 14 | 8 |
| Q4 2018 | 49 | 62 | 59 | 25 | -13 |
| Q1 2019 | 32 | 80 | 44 | 38 | -18 |
| Q2 2019 | 20 | 63 | 55 | 33 | -10 |
| Q3 2019 | 24 | 77 | 44 | 21 | -2 |
| Q4 2019 | 27 | 59 | 71 | 11 | 7 |
| Q1 2020 | 23 | 58 | 50 | 41 | -16 |
| Q2 2020 | 21 | 63 | 52 | 16 | 8 |
| Q3 2020 | 21 | 60 | 55 | 21 | 3 |
| Q4 2020 | 29 | 58 | 62 | 16 | 9 |
| Q1 2021 | 31 | 70 | 64 | 17 | 4 |
| Q2 2021 | 16 | 68 | 62 | 23 | 9 |
| Q3 2021 | 17 | 59 | 72 | 16 | 12 |
| Q4 2021 | 38 | 64 | 66 | 21 | 5 |
| Q1 2022 | 20 | 61 | 72 | 32 | -4 |
| Q2 2022 | 11 | 68 | 56 | 24 | 6 |
| Q3 2022 | 23 | 62 | 47 | 20 | 5 |
Hedge funds changes in Vanda Pharmaceuticals stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 1,336,000 | 10,243,000 |
|---|---|---|
| Q1 2018 | 1,007,000 | 2,177,000 |
| Q2 2018 | 683,000 | 722,000 |
| Q3 2018 | 4,206,000 | 1,462,000 |
| Q4 2018 | 7,344,000 | 5,845,000 |
| Q1 2019 | 1,441,000 | 2,127,000 |
| Q2 2019 | 661,000 | 910,000 |
| Q3 2019 | 378,000 | 1,267,000 |
| Q4 2019 | 738,000 | 3,552,000 |
| Q1 2020 | 311,000 | 2,271,000 |
| Q2 2020 | 984,000 | 5,943,000 |
| Q3 2020 | 1,085,000 | 2,685,000 |
| Q4 2020 | 731,000 | 2,511,000 |
| Q1 2021 | 1,844,000 | 1,819,000 |
| Q2 2021 | 2,536,000 | 2,203,000 |
| Q3 2021 | 2,068,000 | 2,570,000 |
| Q4 2021 | 17,844,000 | 4,854,000 |
| Q1 2022 | 1,022,000 | 735,000 |
| Q2 2022 | 901,000 | 263,000 |
| Q3 2022 | 882,000 | 231,000 |